FireTail Names Timo Rüppell as Vice President of Product
24.1.2023 16:30:00 EET | Business Wire | Press release
FireTail Inc., a disruptor in API security, today announced the appointment of Timo Rüppell to the executive leadership team as Vice President of Product. In conjunction with bringing Rüppell on board, FireTail also opened a new company office in Helsinki, Finland. Historically a strong cybersecurity research center, FireTail looks to expand the company’s talent pool based out of Helsinki and the Baltic States.
Rüppell brings to FireTail a wealth of experience in technology development and team leadership for early stage companies. He will work closely with co-founder and CTO Riley Priddle to define and navigate the development of FireTail’s API security platform. Previously, Rüppell served as CTO at Mapita Ltd. where he was focused on product design, including security, privacy, and compliance management. Earlier in his career, Rüppell leveraged his PhD in theoretical particle physics as a researcher for Helsinki Institute of Physics.
“FireTail is thrilled to welcome Timo to our growing team. With his background and expertise, I am confident Timo will make a lasting impact on the direction of FireTail’s products, as well as the API security market,” said Jeremy Snyder, FireTail co-founder and CEO. “It’s an exciting time for our company as we expand our presence globally, and plant roots in new cities. We look forward to all the collaboration and innovation that will take place at our new office in Helsinki.”
“After another year of watching significant breaches and security incidents at major enterprises play out in the news, the need for a new approach to solving the security threats tied to APIs has never been more clear. I look forward to working with the FireTail team to further their mission of offering simple yet effective API security that makes a positive impact and makes the internet a safer place for everyone,” added Rüppell.
FireTail will be at CloudNativeSecurityCon on Feb. 1-2, 2023 in Seattle, Washington. Visit the team in the Startup Zone to learn more about FireTail’s unique approach to solving API security threats.
The company is actively looking for startup-minded individuals with a passion for application security and cloud technologies to join the team. If you are based in Helsinki and are looking for a new opportunity, learn more about FireTail’s open roles and company culture at firetail.io/careers.
About FireTail
FireTail’s API security platform protects programmable interfaces with inline API call inspection and blocking, API security posture management, centralized API audit, and detection and response capabilities. The cloud-based solution helps organizations scale their API landscape and reduce the attack surface. FireTail makes API security as simple as import, setup, done.
FireTail is headquartered in Northern Virginia, with additional offices in Dublin, Ireland and Helsinki, Finland. To learn more about FireTail’s API security solution visit us at https://firetail.io or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005251/en/
Contact information
Tori Odom
LaunchTech Communications
+1-443-752-5466
todom@golaunchtech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 14:30:00 EEST | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that health systems can sustain this approach over time,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “At ISPOR 2026, Organon
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 09:30:00 EEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 09:00:00 EEST | Press release
Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership enables agentic AI to scale well beyond pilot deployments. With the Experian Ascend Platform natively connected to the ServiceNow AI Platfo
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 19:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulatory compliance on behalf of developers, removing a significant operational and legal barrier for studios looking to distribute through alternat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom